Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Open Access
- 1 September 2021
- journal article
- editorial
- Published by Elsevier in Translational Oncology
- Vol. 14 (9) , 101156
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphomaTranslational Oncology, 2021
- Recent advances in CAR-T cell engineeringJournal of Hematology & Oncology, 2020
- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-AnalysisTransfusion Medicine Reviews, 2019
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceJournal for ImmunoTherapy of Cancer, 2018
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivoNature Biotechnology, 2018
- Chimeric antigen receptor–modified T cells: CD19 and the road beyondBlood, 2018
- Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironmentScientific Reports, 2017